Vertex Pharma (VRTX) Tops Q3 EPS by 23c, provides guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $525.73 -0.74%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
MTEX, NSYS, PLNH, More
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
MTEX, NSYS, PLNH, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.80, $0.23 better than the analyst estimate of $4.57. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.05 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.9-12 billion, versus the consensus of $12.002 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Lulu’s Fashion Lounge Holdings (LVLU) Misses Q2 EPS by 37c
- Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
